Latest News and Press Releases

NEEDHAM, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...

Edmonton, AB, July 29, 2025 (GLOBE NEWSWIRE) -- The University Hospital Foundation (The Foundation) is pleased to announce the recipients of the 2024 Kaye Competition, which funds research and...

NEEDHAM, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...

- IDE approval obtained; U.S. pilot study clinical site launched at Johns Hopkins- Series B round in planning to support pivotal U.S. trial- New CEO appointment signals next phase of growth and...

COMMUNIQUÉ DE PRESSE LE MASITINIB REÇOIT L'AUTORISATION DE LA FDA ET DE L'EMA POUR L’ETUDE CONFIRMATOIRE DE PHASE 3 DANS LE CANCER DE LA PROSTATE MÉTASTATIQUE HORMONO-RESISTANT, AVEC UNE SÉLECTION...

PRESS RELEASE MASITINIB RECEIVES FDA AND EMA AUTHORIZATION FOR CONFIRMATORY PHASE 3 TRIAL IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER, WITH BIOMARKER-DRIVEN PATIENT SELECTION TARGETING...

MetasTx has been awarded a NCI SBIR grant for its integrated diagnostic and therapeutic platform aimed at predicting and preventing prostate cancer.

Philochem Licensing of OncoACP3 to RayzeBio for potential value of up to $1.35bn plus royalties

TORONTO, June 10, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...

Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "Oncology Collaboration and Licensing Deals 2020-2025" report has been added to ResearchAndMarkets.com's offering.Oncology Collaboration and Licensing...